Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of Remifentanil Target Controlled Infusion Combined With Ibuprofen Injection in Gynecologic Endoscopic Surgery of Female Motion Sickness Patients

NCT06232785 is registered in ClinicalTrials.gov with Second Hospital of Jilin University as lead sponsor.

NCT NCT06232785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06232785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of Remifentanil Target Controlled Infusion Combined With Ibuprofen Injection in Gynecologic Endoscopic Surgery of Female Motion Sickness Patients
Lead sponsor
Second Hospital of Jilin University
Phase
Phase 4
Overall status
Completed
Start date
February 1, 2022
Completion date
December 1, 2023
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ibuprofen, motion sickness, postoperative nausea and vomiting